Introduction
Osteosarcoma (OS) is the most common primary malignant bone tumor among adolescents and young adults. Currently, the standard therapies for OS include surgical excision and systemic chemotherapy. However, the efficacy of these therapies for OS is limited and patients with OS, especially patients with metastatic or recurrent OS, have a poor prognosis [1] . Actually, patients with chemoresistant or metastatic OS have a 5-year survival rate of < 30% [2] . Moreover, the available chemotherapeutic drugs, due to poor targeting, can cause many serious side effects [3] . In addition, there is no reliable biomarker for prognosis of OS. Hence, discovery of new biomarkers and therapeutic targets is of significance in management of OS patients.
Angiogenesis is essential for the progression of many types of tumors because the growth of tumors depends on vascular nutrition [4] . Vascular endothelial growth factor (VEGF), particularly VEGFA, is a potent angiogenic factor for blood vessel formation to regulate the progression of tumors [5, 6] . VEGFA can bind to its receptors, such as VEGF receptor 1 (VEGFR1), to activate the phosphoinositide-3-kinase (PI3K)-AKT signaling pathway, which can promote proliferation and angiogenesis in tumors [7] [8] [9] . VEGFA/VEGFR1 signaling has been considered to be a therapeutic target for some types of tumors. Actually, anti-angiogenesis therapies by targeting VEGF have been demonstrated to inhibit the progression of late stage cancers [10, 11] . It is notable that high levels of VEGF expression are associated with poor prognosis of OS, suggesting that VEGFA/VEGFR1 signaling may be important for the progression of OS [12] [13] [14] . However, the regulation of VEGFA and VEGFR1 expression during the development of OS has not been clarified.
miRNAs are important regulators of the expression of their target genes because they can bind to the 3 0 -UTR of their target mRNA to inhibit its expression by promoting its degradation [15] . Previous studies have shown that miRNA-134 (miR-134) acts as a tumor suppressor by targeting FoxM1, Nanog, integrin b1, MAGI2, CCND1, EGFR, ABCC1 and others in non-small cell lung cancer [16] , head and neck carcinoma [17] , hepatocellular carcinoma [18] , human ovarian cancer [19] and renal cell carcinoma [20] . Furthermore, miR-134 expression is down-regulated in OS tissues [21, 22] . However, it is unclear whether miR-134 regulates VEGFA/VEGFR1 signaling and progression of OS.
In this study, we examined the relative levels of miR-134, VEGFA and VEGFR1 expression in OS and non-tumor bone tissues as well as OS cells. We further investigated the effect of miR-134 overexpression on the proliferation and apoptosis of Saos-2 cells and their secretion of proangiogenic factors, and the growth and angiogenesis of OS in vivo and explored the potential targets of miR-134 in vitro. Our data indicated that the levels of miR-134 expression were associated inversely with VEGFA and VEGFR1 expression in OS, and miR-134 overexpression inhibited the proliferation and angiogenesis of OS by targeting VEGFA/VEGFR1-AKT signaling. Therefore, miR-134 is a tumor suppressor and may be an antiangiogenic factor for OS.
Results

miR-134 expression is significantly downregulated in human OS cell lines and tissues
To investigate the expression pattern of miR-134, we first examined the expression levels of miR-134 in human OS MG-63, U2-OS and Saos-2 cells, primary osteoblasts, 11 OS tissues and six non-tumor bone tissues by quantitative real-time PCR (qRT-PCR). The relative levels of miR-134 in MG-63, U2-OS and Saos-2 cells were similar and significantly lower than that in osteoblasts (P = 0.011, Fig. 1A) . Similarly, the relative levels of miR-134 in OS tissues were significantly lower than that in the non-tumor bone tissues (P < 0.0001, Fig. 1B) . The results suggest that miR-134 expression was significantly down-regulated in human OS.
miR-134 inhibits the proliferation of Saos-2 cells and their secretion of angiogenesis factors in vitro
To determine the biological function of miR-134, Saos-2 cells were transfected with miR-134 mimic or control scramble miRNA for 48 h. The positive fluorescence cells accounted for > 90% (data not shown). qRT-PCR indicated that transfection with miR-134 increased the relative levels of miR-134 expression by near 600-fold (P < 0.0001, Fig. 2A ). Longitudinal counting of the numbers of cells revealed that while the numbers of control cells increased with time the number of miR-134-transfected cells only slightly increased at 2 days post-culture and decreased gradually (P < 0.001, Fig. 2B ). The number of miR-134-transfected cells was significantly less than that of controls at 3-5 days post-culture. Such data suggest that miR-134 overexpression may inhibit the proliferation of Saos-2 and MG-63 cells.
In addition, flow cytometry analysis indicated that induction of miR-134 overexpression significantly increased the percentage of apoptotic Saos-2 cells (12.7% vs. 3.8%, P < 0.05, Fig. 2C ) and western blot analysis revealed that miR-134 overexpression increased the relative levels of cleaved poly (ADPribose) polymerase (PARP) in Saos-2 cells (Fig. 2D) . Furthermore, we evaluated the effect of miR-134 overexpression on angiogenesis in human umbilical vein endothelial cells (HUVECs) by the tube formation assay. HUVECs were cultured in medium containing 50% of the conditioned medium from the cultured Saos-2 cells that had been transfected with control or 10 or 40 nM miR-134 mimic and/or 10 ngÁmL À1 of VEGF 165 protein for 24 h. One day later, the generated tubular structures were imaged and the relative ratios of tube length to the control were calculated. Clearly, culture with the conditioned medium from both 10 and 40 nM of miR-134-transfected Saos-2 cells significantly inhibited the tube formation in HUVECs in a dose-dependent manner (P < 0.0001, Fig. 2E ). Treatment with VEGF significantly enhanced the tube formation and abrogated the inhibition of 10 nM miR-134-transfected conditioned medium (P < 0.01; Fig. 2F ). Hence, miR-134 overexpression inhibited the proliferation and suppressed the secretion of angiogenic stimulators, but promoted the apoptosis of Saos-2 cells.
miR-134 inhibits tumor growth and angiogenesis in mice
To evaluate the effect of miR-134 on OS growth in vivo, Saos-2 cells were transduced with LV-miR-134 or LV-Control to generate miR-134 stably expressing Saos-2/miR-134 and Saos-2/Control cells, respectively. Subsequently, BALB/c nude mice were implanted subcutaneously with 10 6 Saos-2/miR-134 or Saos-2/Control cells. The dynamic growth of implanted tumors was monitored. As shown in Fig. 3A ,B, miR-134 overexpression significantly inhibited the growth of implanted tumors (P < 0.001) and reduced the tumor weights (1.288 AE 0.147 vs. 2.643 AE 0.686 g, P < 0.001; Fig. 3C ). qRT-PCR analysis showed that the levels of miR-134 expression in the Saos-2/miR-134 tumors were significantly higher than that in the Saos-2/Control tumors (P < 0.001; Fig. 3D ). Thus, miR-134 overexpression inhibited the growth of implanted OS tumors in vivo.
To examine whether miR-134 could suppress angiogenesis in OS tumor, the tumor blood flow (angiogenesis) in individual tumors at 3 weeks post-inoculation was measured by fluorescence molecular tomography (FMT) using the AngioSense probe. The fluorescence signals in the mice with Saos-2/miR-134 tumors were significantly less than those in the mice with Saos-2/ Control tumors (P = 0.0013, Fig. 3E ). qRT-PCR analysis showed that the relative levels of VEGFA and VEGFR1 mRNA transcripts in the Saos-2/miR-134 tumors were significantly lower than those in the Saos-2/Control tumors (P < 0.0001, Fig. 3F ). Western blot analysis indicated that the relative levels of VEGFA and VEGFR1 expression in the Saos-2/miR-134 tumors were obviously lower than those in the Saos-2/ Control tumors (Fig. 3G ). Immunohistochemistry revealed that the level of CD31 expression in the Saos-2/miR-134 tumors was clearly lower than that in the Saos-2/Control tumors (Fig. 3H) . Collectively, these data demonstrated that miR-134 overexpression inhibited the growth and angiogenesis of OS tumor in vivo.
miR-134 suppresses VEGFA and VEGFR1 expression in OS VEGF/VEGFR1 signaling is crucial for angiogenesis in many types of tumors [23] [24] [25] . We detected significantly higher levels of VEGFA and VEGFR1 expression in human OS tumors than in non-tumor bone tissues (P < 0.001, Fig. 4A,B) . To explore the regulatory effect of miR-134 on VEGFA expression, Saos-2 cells were transfected with different doses of miR-134 mimic and the levels of VEGF in the supernatants of cultured cells were measured by ELISA (P < 0.001, Fig. 4C ). Transfection with different doses of miR-134 mimic decreased the levels of VEGF in the supernatants in a dose-dependent manner. Furthermore, transfection with miR-134 mimic for varying periods also reduced the secretion of VEGF in a time-dependent manner (P < 0.0001, Fig. 4D ). Similarly, transfection with miR-134 mimic significantly reduced the VEGF and VEGFR1 expression in both Saos-2 and MG-63 cells (P < 0.001; Fig. 4E ,F). Finally, western blot analysis indicated that the levels of VEGF and VEGFR1 expression in the Saos-2 and MG-63 cells that had been transfected with miR-134 were significantly lower than that in the controls (Fig. 4G) .
Together, such data clearly demonstrated that miR-134 overexpression inhibited VEGF and VEGFR1 expression in OS cells.
miR-134 represses OS growth and angiogenesis by directly targeting the VEGFA/VEGFR1-AKT pathway in OS
VEGFA/VEGFR1 signaling is crucial for angiogenesis and progression of many types of tumors [26] . Given that miR-134 inhibited angiogenesis in OS cells and in vivo, we searched for potential interaction between miR-134 and VEGFA and VEGFR1 mRNAs by bioinformatics. The 3 0 -UTR of VAGFA and VAGFR1 mRNAs had a motif for potential miR-134 binding (Fig. 5A ). Subsequently, dual luciferase assays indicated that co-transfection with the luciferase reporter containing the 3 0 -UTR of VEGFA, together with miR-134 mimic, but not the control miRNA, significantly reduced the levels of luciferase activity in Saos-2 cells (P < 0.0001, Fig. 5B ). However, co-transfection with the luciferase reporter containing the mutant 3 0 -UTR of VEGFA, together with miR-134 did not alter the levels of luciferase activity in Saos-2 cells. A similar pattern of luciferase activity was detected with cotransfection with the luciferase reporter containing the 3 0 -UTR of VEGFR1 together with miR-134 mimic in Saos-2 cells (P < 0.0001, Fig. 5B ). Such data suggest that miR-134 may bind to the 3 0 -UTR of VEGFA and VEGFR1 mRNAs to inhibit their expression in Saos-2 cells.
Engagement of VEGFR1 by VEGFA can activate the downstream PI3K-AKT signaling pathway, which is important for cell proliferation and angiogenesis [27] [28] [29] . To understand the consequence of miR-134 inhibiting pro-angiogenic factor expression in OS, we studied the effect of miR-134 overexpression on AKT expression and phosphorylation in Saos-2 cells. As shown in Fig. 5D , induction of miR-134 overexpression significantly reduced the relative levels of AKT expression and phosphorylation in Saos-2 cells. Proliferating cell nuclear antigen (PCNA) is a marker for cell proliferation [30, 31] . To further understand the consequence of miR-134 action, we tested the effect of miR-134 on the relative levels of PCNA expression in OS cells. We found that miR-134 overexpression significantly decreased the relative levels of PCNA expression in Saos-2 cells. Therefore, miR-134 inhibited the proliferation and angiogenesis of OS cells by targeting VEGFA and VEGFR1 to attenuate AKT signaling.
Discussion
In the current study, our novel findings provide evidence that miR-134 inhibits the progression and angiogenesis of OS by targeting VEGFA/VEGFR1 signaling. First, we found that the levels of miR-134 in OS tissues were significantly lower than those in nontumor bone tissues. These data were consistent with previous reports, supporting the notion that dysregulated miRNA expression is implicated in the development and progression of OS [32] [33] [34] . Furthermore, we detected significantly up-regulated VEGFA and VEGFR1 expression in OS tissues. Given that VEGFA/VEGFR1 signaling is crucial for the progression and angiogenesis of OS [12] [13] [14] , the inverse association between miR-134 expression and VEGFA and VEGFR1 expression suggests that miR-134 may act as a tumor suppressor in inhibiting the progression and angiogenesis in OS. Hence, our findings may also provide new insights into the pathogenesis of OS. We are interested in further investigating the potential † P < 0.05, *P < 0.01, **P < 0.001, # P < 0.0001. correlation between OS characteristics and miR-134 expression in the future when more samples are available. Previous studies have shown that miR-134 targets FoxM1, Nanog, integrin b1, MAGI2, CCND1, EGFR, ABCC1, STAT5B, Hsp90, GOLPH3, ITGB1, Bcl-2 and others to inhibit the development and progression of several types of cancers [16] [17] [18] [19] [20] . In this study, we employed bioinformatics to find that the 3 0 -UTR of VEGFA and VEGFR1 contained the motif of miR-134 binding and transfection with miR-134 mimic, together with the luciferase reporter containing the wild-type 3 0 -UTR of VEGFA or VEGFR1, but not their mutants, significantly reduced the levels of luciferase activity. Such data suggest that miR-134 may bind to the 3 0 -UTR of VEGFA and VEGFR1. Our findings extended previous observations [21] and suggest that miR-134 may have prefered targets in different types of tumors. Although one type of miRNA can bind to many targets, to the best of our knowledge, this is the first report that miR-134 can simultaneously bind to the receptor and its ligand to inhibit VEGFA/VEGFR1 signaling.
VEGFA/VEGFR1-mediated angiogenesis is crucial for the progression of tumors [35, 36] . VEGFA through VEGFR1 can stimulate endothelial cell proliferation and neovascularization in tumors [37] . In this study, we found that induction of miR-134 overexpression significantly inhibited the proliferation of OS cells and the growth of implanted OS tumors in mice. Activation of the PI3K-AKT signaling pathway is necessary for proliferation of tumor cells and angiogenesis in the tumors. Actually, engagement of VEGFR1 by VEGFA can activate the PI3K-AKT signaling pathway [23] . Inhibition of VEGFA/VEGFR1 signaling can also down-regulate the AKT activation in tumor cells [28] . In this study, we found that miR-134 overexpression inhibited the proliferation of OS cells and increased apoptosis in Saos-2 cells. miR-134 overexpression not only attenuated the VEGFA and VEGFR1 expression, but also decreased the AKT activation and PCNA expression in Saos-2 cells. These findings explained why miR-134 simultaneously inhibited the growth of implanted tumor and angiogenesis in the tumor. It is possible that during the development and progression of OS, aberrant activation of VEGFA/VEGFR1 signaling, together with downregulated miR-134 expression, may enhance PI3K-AKT activation to promote the progression and angiogenesis of OS. Therefore, our findings may provide new insights into the pathogenesis of OS. We recognize that our study had limitations of small sample size, lack of miR-134-based therapeutic application and lack of potential mechanisms underlying the regulation of miR-134 on the development and progression of OS. We are interested in further investigations to address these limitations and explore the mechanisms underlying the action of miR-134 in regulating the progression of OS.
Materials and methods
Ethics statement
The experimental protocols were approved by the Ethics Review Committee of Shanxi Medical University (2017LL077), Taiyuan, Shanxi, China. Written informed consent was obtained from all the parents/legal guardians of all patients included in this study. The study was approved by the local ethics committee of Shanxi Medical University and performed in accordance with the standards set by the Declaration of Helsinki.
Primary human OS specimens
A total of 11 human surgical OS samples from patients and five non-tumor bone tissues were obtained from patients with OS. The samples were preserved in RNA Save Solution (BI, Israel) or snap-frozen in liquid nitrogen.
Cell culture
Human OS Saos-2 and MG-63 cells were cultured in RPMI 1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% heat-inactivated fetal bovine serum (Thermo Fisher Scientific), 100 unitsÁmL À1 of penicillin and 100 lgÁmL À1 of streptomycin at 37°C in a humidified atmosphere of 5% CO 2 [42, 43] . Human OS U2-OS and osteoblast cells were cultured in 10% fetal bovine serum-containing Dulbecco's modified Eagle's medium [32] . HUVECs were obtained from ATCC (Manassas, VA, US), and cultured in Endothelial Growth Basal medium (PromoCell; MiaoTong Bio., Shanghai, China), according to the manufacturer's protocol. Other cells were purchased from the Chinese Academy of Sciences Type Culture Collection (Shanghai, China). 
Cell transfection and transduction
Flow cytometry analysis of cell apoptosis
The impact of miR-134 overexpression on apoptosis of Saos-2 cells was determined by flow cytometry [44] . Briefly, after transfection with miR-134 mimics or control miRNA, the cells (5 9 10 5 /tube) were stained in duplicate with 10 lL annexin V-FITC and 12 lL propidium iodide (PI; KeyGen, Nanking, China) for 15 min in the dark. After being washed, the percentages of FITC + apoptotic cells were analyzed by flow cytometry on a flow cytometer (FACSCalibur System, BD, Franklin Lakes, NJ, USA). The data were analyzed by FLOWJ software.
Quantitative reverse transcription PCR
Total RNA and miRNAs were extracted from OS tissues and cells using TRIzol reagent (Thermo Fisher Scientific) and miRNeasy Mini Kit (Qiagen, Germantown, MD, USA), respectively. The quality and quantity of total RNA samples were tested using a NanoDrop 2000C spectrophotometer (Thermo Fisher Scientific). A preparation of RNA with an A 260 /A 280 ratio of 1.8-2.0 was used for analysis of the mRNA and miRNA expression. Individual RNA samples (1 lg per sample) were reverse transcribed into cDNA using the PrimeScript RT Master Mix kit (Takara, Shiga, Japan), according to the manufacturer's instructions. The relative levels of target gene mRNA to the control 18S rRNA transcripts were determined by qRT-PCR using the SYBR Premix Ex TaqTM (Takara) and the specific primers in the IQ5 Multicolor Real-Time PCR Detection system (Bio-Rad Laboratories, Hercules, CA, USA). Similarly, the relative levels of miR-134 to the control U6 transcripts were also determined by qRT-PCR. 
Western blot analysis
The relative levels of target protein to the control b-actin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression were determined by western blot analysis [46] . Briefly, the tissue samples were homogenized and cell samples were lyzed in RIPA lysis buffer containing PMSF, protease and phosphatase inhibitors (Keygen). After centrifugation, the concentrations of total proteins in individual samples were determined by bicinchoninic acid. 
ELISA
The concentrations of VEGF in the supernatants of cultured cells or tissue lysates were determined by ELISA using the Human VEGF Quantikine ELISA kits (Abcam, Cambridge, MA, USA) according to the manufacturer's instructions. The experimental and control samples in triplicate were tested simultaneously. The concentrations of VEGF were normalized to the concentrations of total proteins in the supernatants of tissue lysates and calculated using the standard curve established using pure VEGF provided. 
HUVEC angiogenesis assay
Immunohistochemistry
The xenograft tumor tissues were fixed with 10% buffered formalin for 2 days and the tumor sections (4 lm) were dewaxed, rehydrated and blocked with 5% BSA. The sections were stained with anti-CD31 (BioWorld, Nanjing, China) at 37°C for 2 h. After being washed, the sections were incubated with HRP-conjugated anti-mouse IgG (ZSGB-BIO, Beijing, China) at 37°C for 1 h and counterstained with hematoxylin. The intensity of anti-CD31 staining was analyzed using an automatic digital slide scanner and Scanner Control Software (Pannoramic MIDI II, 3DHISTECH, Budapest, Hungary). 
Mouse model and bioimaging analysis
Bioinformatics analysis
The potential targets and potential miRNAs for VEGFR1 were analyzed using specific programs of TARGETSCAN (http://www.targetscan.org), MIRBASE (http://www.mirbase. org), and MIRANDA (http://www.microrna.org).
Statistical analysis
Statistical analysis was performed with PRISM 5 (GraphPad Software, La Jolla, CA, USA). Data are expressed as the mean AE SEM. The difference among the groups was tested by one-way ANOVA and post hoc Tukey's multiple comparisons and the difference between groups was analyzed by Student's t test. Statistical significance was accepted with a P-value of < 0.05.
